Skip to main content

Table 3 Hazard ratios of overall survival for several basic characteristics by breast cancer subtyping

From: Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

   

Molecular subtyping

 

All

      

Five subtypes

Four subtypes

Variables

(N = 951)

IHC-Luminal A

(N = 486)

IHC-Luminal B

(N = 123)

IHC-HER2

(N = 113)

IHC-BLBC

(N = 139)

IHC-QNBC/5NP

(N = 90)

IHC-TNBC

(N = 229)

 

HR(N of event)

HR(N of event)

HR(N of event)

HR(N of event)

HR(N of event)

HR(N of event)

HR(N of event)

 

(95%CI)

p-value

(95%CI)

p-value

(95%CI)

p-value

(95%CI)

p-value

(95%CI)

p-value

(95%CI)

p-value

(95%CI)

p-value

Age Group (yr)

              

   < 50

1.00(85/590)

 

1.00(22/297)

 

1.00(14/87)

 

1.00(21/51)

 

1.00(17/97)

 

1.00(11/58)

 

1.00(28/155)

 

   ≥ 50

0.99(52/361)

 

1.43(20/189)

 

1.42(8/36)

 

0.32(9/62)

 

0.92(7/42)

 

1.23(8/32)

 

1.08(15/74)

 
 

(0.70-1.39)

0.96

(0.78-2.61)

1.0

(0.59-3.37)

1.0

(0.15-0.71)

0.04

(0.38-2.20)

1.0

(0.49-3.04)

1.0

(0.58-2.03)

1.0

Tumor size (cm)

              

   ≤ 2 cm

1.00(28/392)

0.005

1.00(7/228)

 

1.00(5/39)

 

1.00(6/35)

 

1.00(6/52)

 

1.00(4/38)

 

1.00(10/90)

 

   2-5 cm

2.61(87/493)

 

4.21(30/231)

 

1.29(14/75)

 

1.93(19/64)

 

1.36(12/76)

 

2.78(12/47)

 

1.86(24/123)

 
 

(1.70-4.00)

< 0.001

(1.94-10.1)

0.001

(0.46-3.61)

1.0

(0.77-4.83)

1.0

(0.51-3.64)

0.65

(0.89-8.63)

0.62

(0.88-3.88)

0.010

   > 5cm

5.34(22/66)

 

6.55(5/27)

 

2.17(3/9)

 

2.46(5/14)

 

6.65(6/11)

 

7.76(3/5)

 

7.54(9/16)

 
 

(3.05-9.33)

< 0.001

(2.08-20.6)

0.008

(0.51-9.16)

1.0

(0.75-8.08)

1.0

(2.13-20.3)

0.008

(1.73-34.5)

0.046

(3.12-18.2)

< 0.001

LN involvement

              

   Negative

1.00(39/498)

 

1.00(7/246)

 

1.00(7/52)

 

1.00(12/63)

 

1.00(8/89)

 

1.00(5/48)

 

1.00(13/137)

 

   Positive

2.93(98/453)

 

4.88(35/240)

 

1.55(15/71)

 

2.23(18/50)

 

4.6(16/50)

 

3.96(14/42)

 

3.99(30/92)

 
 

(2.03-4.24)

< 0.001

(2.25-10.45)

< 0.001

(0.63-3.81)

1.0

(1.07-4.62)

0.26

(1.73-9.49)

0.004

(1.43-11.0)

0.064

(2.09-7.35)

< 0.001

AJCC stage

              

   I

1.00(10/254)

 

1.00(0/148)

 

1.00(2/19)

 

1.00(3/22)

 

1.00(2/38)

 

1.00(3/27)

 

1.00(5/65)

 

   II

3.29(58/467)

 

NA*(21/221)

 

1.09(10/69)

 

1.70(13/57)

 

2.74(11/78)

 

0.72(3/42)

 

1.58(14/120)

 
 

(1.68-6.43)

0.001

  

(0.23-5.01)

1.0

(0.48-5.97)

1.0

(0.61-12.3)

1.0

(0.14-3.58)

1.0

(0.57-4.40)

1.0

   III

8.74(69/230)

 

NA*(21/117)

 

2.60(10/35)

 

3.53(14/34)

 

11.36(11/23)

 

7.85(13/21)

 

9.16(24/44)

 
 

(4.50-16.9)

< 0.001

  

(0.57-11.9)

1.0

(1.01-12.34)

0.37

(2.57-51.3)

0.016

(2.23-27.5)

0.005

(3.49-24.0)

< 0.001

Adjuvant chemotherapy

              

   Not done

1.00(35/155)

 

1.00(12/95)

 

1.00(9/20)

 

1.00(7/22)

 

1.00(6/10)

 

1.00(1/8)

 

1.00(7/18)

 

   Done

0.59(102/796)

 

0.74(30/391)

 

0.23(13/103)

 

0.75(23/91)

 

0.17(18/129)

 

2.23(18/82)

 

0.41(36/211)

 
 

(0.40-0.87)

0.008

(0.37-1.45)

1.0

(0.09-0.52)

0.007

(0.32-1.74)

1.0

(0.07-0.43)

< 0.001

(0.29-16.7)

1.0

(0.18-0.93)

0.06

  1. * There is no event in AJCC stage I of luminal A subtype.
  2. IHC: immunohistochemistry, LN: lymph node
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us